Metastasis-free survival as a surrogate endpoint in prostate cancer clinical trials

As many readers will have realized, the major regulatory authorities started, some time ago, to accept prostate cancer progression-free survival of differing types as a surrogate for overall survival in the approval of some drugs for the treatment of prostate cancer. … READ MORE …

Nuts to the Daily Telegraph … and nuts for most of our readers!

Finally, we may have the perfect paper that illustrates the critical difference between overall mortality rates and cancer-specific cancer rates among men with prostate cancer, and how affecting one may have no effect whatsoever on the other! … READ MORE …

What does a very high PSA at diagnosis tell us?

Probably because of high level of research funding as a consequence of the Movember Foundation‘s initiatives, Australia is increasingly providing us with interesting data on the diagnosis, management, and outcomes of men with prostate cancer. … READ MORE …

Statin use and all-cause mortality among prostate cancer patients

Yet another study involving a large number of patients (this one from Taiwan) has again concluded that men with prostate cancer who take statins are less likely to die within a definable time period than men with prostate cancer who are not taking statins. … READ MORE …

Survival of men with mCRPC who receive no additional life-prolonging treatment

A new article in the Scandinavian Journal of Urology provides us with some insight — from relatively recent data — into the survival times of men with metastatic, castration-resistant prostate cancer (mCRPC) after prior treatment with androgen deprivation therapy (ADT) but who either decline or do not receive any further form of life-prolonging therapy. … READ MORE …

Does regular aspirin therapy improve survival of prostate cancer patients?

An open-access, full text article in the April issue of the Journal of Urology addresses long-standing questions about the impact of regular aspirin use on the long-term outcomes of men diagnosed with and treated for prostate cancer. … READ MORE

Non-prostate cancer-specific mortality rates in a cohort of > 3,000 patients

The issue of how long a man who is newly diagnosed with localized prostate cancer is likely to live before he dies a natural death from other causes is a crucial element in the decision whether to undergo treatment (and how aggressive that treatment may need to be). … READ MORE …